Home > Healthcare > Biotechnology > Biopharma > Circulating Tumor Cells (CTC) Market

Circulating Tumor Cells (CTC) Market Trends

Report ID: GMI6095
Published Date: Jun 2023
Report Format: PDF

Download Free Sample

Circulating Tumor Cells Market Trends

Increasing number of cancer cases globally will have a positive impact on the market value. For instance, as per the American Cancer Society, in 2022, the total number of new cancer cases were 1.9 million and 609,360 cancer deaths in the U.S. alone. As cancer prevalence rises, there is a growing need for effective cancer diagnostics and monitoring tools along with CTC-based assays and technologies. This presents a significant opportunity for companies operating in the market to develop innovative products and solutions that enable the detection, enumeration, and molecular characterization of CTCs. Additionally, the growing interest in liquid biopsy approaches further fuels the demand for CTC-based technologies, as they offer a non-invasive method for real-time monitoring of cancer patients.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global market for circulating tumor cells size was USD 11.1 billion in 2022 and will reach USD 33.5 billion by end of 2032 owing to the rising demand for effective diagnostic and treatment solutions.

Circulating tumor cells industry share from the research application segment recorded USD 8.1 billion in 2022 driven by increasing adoption in cancer research to offer valuable insights into tumor biology and cancer prognosis.

North America held 42.4% of the circulating tumor cells market share in 2022 and is anticipated to expand considerably through 2032 due to the increasing advancements in diagnostic technologies

Thermo Fisher Scientific Inc., QIAGEN, Precision for Medicine, BIOCEPT, Inc., BioFluidica, Fluxion Biosciences, Inc., Greiner Bio One International GmbH, Ikonisys Inc., Miltenyi Biotec, IVDiagnostics, and Biolidics Limited are some prominent firms providing circulating tumor cells.